Postablation德-γ羧基凝血酶原水平预测预后乙肝相关性肝癌

StephenW

Postablation Des-gamma-carboxy Prothrombin Level Predicts Prognosis in Hepatitis B-related Hepatocellular Carcinoma

    Sunyoung Lee, Hyunchul Rhim*, Young-sun Kim, Tae Wook Kang andKyoung Doo Song

DOI: 10.1111/liv.12991

This article is protected by copyright. All rights reserved.

Issue
Cover image for Vol. 35 Issue 11
Liver International

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

Additional Information(Show All)

Author Information
Publication History
Author Information

    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

* Correspondence to Hyunchul Rhim, MD
Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul 135-710, Republic of Korea
Tel: +82-2-3410-2507
Fax: +82-2-3410-2559
E-mail: [email protected]

    This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/liv.12991


Keywords:

    Hepatitis B virus;Hepatocellular carcinoma;Radiofrequency ablation;des-gamma-carboxy prothrombin

Abstract
Background & Aims

We investigated whether pre- or postablation serum alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) levels can predict prognosis in patients with curative radiofrequency ablation (RFA) for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).
Methods

We retrospectively analyzed 412 patients with HBV-related single HCC treated with percutaneous RFA between January 2004 and December 2013. AFP and DCP levels were measured before (preablation) and 1 month after treatment (postablation). We assessed predictive factors for overall and recurrence-free survival.
Results

On univariate analysis, Child-Pugh score, MELD score, platelet count, tumor size, Barcelona Clinic Liver Cancer (BCLC) stage, and pre- and postablation DCP were significant for overall survival; and age, Child-Pugh score, MELD score, platelet count, tumor size, Cancer of the Liver Italian Program (CLIP) score, BCLC stage, and pre- and postablation AFP and DCP were significant for recurrence-free survival. Multivariate analysis revealed significant differences in overall survival by MELD score and tumor size and in recurrence-free survival by BCLC stage. Among the tumor markers, postablation DCP was an independent prognostic factor for overall and recurrence-free survival (hazard ratio [HR], 3.438; 95% confidence interval [CI], 1.331–8.877; p = 0.011 and HR, 4.934; 95% CI, 2.761–8.816; p < 0.001, respectively). Postablation AFP was associated with recurrence-free survival (HR, 1.995; 95% CI, 1.476–2.697; p <0.001) but not overall survival.
Conclusions

In patients with HBV-related HCC, postablation serum DCP is a useful biomarker for predicting survival and recurrence after curative RFA.

This article is protected by copyright. All rights reserved.

StephenW

Postablation德-γ羧基凝血酶原水平预测预后乙肝相关性肝癌

    生友利，Hyunchul Rhim *，杨淳金，泰旭康andKyoung斗歌

DOI：10.1111 / liv.12991

这篇文章是受版权保护的。版权所有。

问题
封面图片卷。 35第11期
肝国际

接受第（接受，未编辑的文章在网上和可引用出版。最后编辑记录的排版本将出现在未来的。）

其他信息（显示所有）

作者信息
出版历史
作者信息

    放射学和中心部影像科学，三星医疗中心，韩国成均馆大学医学院，首尔，韩国

*通讯作者Hyunchul Rhim，MD
放射学和中心部影像科学，三星医疗中心，韩国成均馆大学医学院，81，Irwon-RO，江南区，首尔135-710，韩国
联系电话：+ 82-2-3410-2507
传真：+ 82-2-3410-2559
电子信箱：[email protected]

    这篇文章已被接受发表，并经过充分的同行评审，但经过审稿，排版，分页和校对过程中，这可能会导致这个版本和记录的版本之间的差异还没有。请引用这篇文章的DOI：10.1111 / liv.12991


关键词：

    乙型肝炎病毒;肝细胞癌;射频消融;脱-γ-羧基凝血酶原

抽象的
背景和目的

我们调查是否前或postablation血清甲胎蛋白（AFP）和DES-γ羧基凝血酶原（DCP）水平可以预测预后的治疗射频消融（RFA），乙型肝炎病毒（HBV）相关肝细胞癌（HCC ）。
方法

我们回顾性分析412例HBV相关肝癌单用治疗经皮射频消融2004年1月之间的2013年AFP和DCP水平（preablation）和1个月后处理（postablation）前测量。我们评估的预测因素的整体和无复发生存率。
结果

单变量分析显示，Child-Pugh评分，MELD评分，血小板计数，肿瘤大小，巴塞罗那临床肝癌（BCLC）阶段，前和postablation DCP是总生存显著;和年龄，Child-Pugh评分，MELD评分，血小板计数，肿瘤大小，肝脏意大利计划（CLIP）分数，BCLC阶段，前和postablation AFP和DCP有显著的无复发生存率的癌症。多变量分析显示由MELD评分与肿瘤的大小和无复发生存率由BCLC阶段的总生存期显著的差异。在这些肿瘤标志物，postablation DCP是一个独立的预后因素的整体和无复发生存率（危险比（HR），3.438; 95％可信区间[CI]，1.331-8.877; P = 0.011和HR，4.934; 95％ CI，2.761-8.816; P <0.001）。 Postablation AFP与无复发生存率（HR，1.995; 95％CI，1.476-2.697; P <0.001），但不总生存期。
结论

在例HBV相关的肝癌，postablation血清DCP是射频消融治疗后预测的生存和复发的一个有用的生物标志物。

这篇文章是受版权保护的。版权所有。